Leap Investments’s Unity Biotechnology UBX Stock Holding History

Leap Investments’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,340	Closed	-$78K	–	570
2020 Q1	$78K	Buy	+1,340	New	+$84.5K	0.11%	295

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Leap Investments's UBX Position: Q2 2020 in Review

Leap Investments sold out of Unity Biotechnology (UBX) in Q2 2020, closing a stake of 1,340 shares — an estimated $78K sold.

Leap Investments first reported a position in UBX in Q1 2020 and held it in 1 quarter. The position peaked at $78K in Q1 2020. 84 funds tracked by Wall St. Rank hold UBX as of Q2 2020.

Leap Investments reported no remaining Unity Biotechnology position as of Q2 2020 after selling out during the quarter.
Leap Investments sold 1,340 Unity Biotechnology shares in Q2 2020, an estimated $78K.
Leap Investments first reported a position in Unity Biotechnology in Q1 2020 and held it in 1 quarter.
Leap Investments's Unity Biotechnology position peaked at $78K in Q1 2020.
84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.